Mario Losen

List of Publications by Year
in descending order

90 papers	4,229 citations	126708 33 h-index	114278 63 g-index
91 all docs	91 docs citations	91 times ranked	4624 citing authors

#	Article	IF	Citations
1	Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange. Science, 2007, 317, 1554-1557.	6.0	846
2	A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. Journal of Autoimmunity, 2014, 52, 139-145.	3.0	244
3	MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20783-20788.	3.3	234
4	Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain, 2012, 135, 1081-1101.	3.7	180
5	Effect of oxygen limitation and medium composition on Escherichia coli fermentation in shake-flask cultures. Biotechnology Progress, 2004, 20, 1062-1068.	1.3	161
6	Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmunity Reviews, 2013, 12, 918-923.	2.5	143
7	The lipid droplet coat protein perilipin 5 also localizes to muscle mitochondria. Histochemistry and Cell Biology, 2012, 137, 205-216.	0.8	136
8	Advances in understanding and modeling the gasâ€“liquid mass transfer in shake flasks. Biochemical Engineering Journal, 2004, 17, 155-167.	1.8	123
9	Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia Gravis. Journal of Immunology, 2011, 186, 2503-2513.	0.4	115
10	Antibody effector mechanisms in myasthenia gravisâ€"Pathogenesis at the neuromuscular junction. Autoimmunity, 2010, 43, 353-370.	1.2	101
11	Main Immunogenic Region Structure Promotes Binding of Conformation-Dependent Myasthenia Gravis Autoantibodies, Nicotinic Acetylcholine Receptor Conformation Maturation, and Agonist Sensitivity. Journal of Neuroscience, 2009, 29, 13898-13908.	1.7	93
12	IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. Journal of Autoimmunity, 2017, 77, 104-115.	3.0	92
13	Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain, 2005, 128, 2327-2337.	3.7	66
14	In vivo electroporation of the central nervous system: A non-viral approach for targeted gene delivery. Progress in Neurobiology, 2010, 92, 227-244.	2.8	66
15	ILâ€17â€producing CD4⁺ T cells contribute to the loss of Bâ€cell tolerance in experimental autoimmune myasthenia gravis. European Journal of Immunology, 2015, 45, 1339-1347.	1.6	64
16	MuSK autoantibodies in myasthenia gravis detected by cell based assay â€" A multinational study. Journal of Neuroimmunology, 2015, 284, 10-17.	1.1	63
17	Absence of<i>N</i>-Methyl-_{<scp>D</scp>}-Aspartate Receptor IgG Autoantibodies in Schizophrenia. JAMA Psychiatry, 2015, 72, 731.	6.0	58
18	Titin antibodies in â€œseronegativeâ€•myasthenia gravis â€" A new role for an old antigen. Journal of Neuroimmunology, 2016, 292, 108-115.	1.1	57

#	Article	IF	Citations
19	Muscle disuse atrophy is not accompanied by changes in skeletal muscle satellite cell content. Clinical Science, 2014, 126, 557-566.	1.8	55
20	Sphingolipids in Alzheimer's disease, how can we target them?. Advanced Drug Delivery Reviews, 2020, 159, 214-231.	6.6	53
21	Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors â€" Recommendations for methods and experimental designs. Experimental Neurology, 2015, 270, 18-28.	2.0	51
22	The auto-antigen repertoire in myasthenia gravis. Autoimmunity, 2010, 43, 380-400.	1.2	48
23	B cell characterization and reactivity analysis in multiple sclerosis. Autoimmunity Reviews, 2009, 8, 654-658.	2.5	47
24	Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Specific Autoantibody Production in Primary Thymic Cell Cultures from Early-Onset Myasthenia Gravis Patients. Journal of Immunology, 2014, 193, 1055-1063.	0.4	45
25	Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients. JCI Insight, 2019, 4, .	2.3	43
26	Effect of oxygen supply on passaging, stabilising and screening of recombinant production strains in test tube cultures. FEMS Yeast Research, 2003, 4, 195-205.	1.1	41
27	DGAT1 overexpression in muscle by in vivo DNA electroporation increases intramyocellular lipid content. Journal of Lipid Research, 2005, 46, 230-236.	2.0	41
28	Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor. Journal of Autoimmunity, 2014, 52, 101-112.	3.0	41
29	Paradoxical Increase in TAG and DAG Content Parallel the Insulin Sensitizing Effect of Unilateral DGAT1 Overexpression in Rat Skeletal Muscle. PLoS ONE, 2011, 6, e14503.	1.1	39
30	The Effect of Plasma From Muscle-Specific Tyrosine Kinase Myasthenia Patients on Regenerating Endplates. American Journal of Pathology, 2009, 175, 1536-1544.	1.9	37
31	Protein Supplementation Augments Muscle Fiber Hypertrophy but Does Not Modulate Satellite Cell Content During Prolonged Resistance-Type Exercise Training in Frail Elderly. Journal of the American Medical Directors Association, 2017, 18, 608-615.	1.2	37
32	A novel method for making human monoclonal antibodies. Journal of Autoimmunity, 2010, 35, 130-134.	3.0	36
33	Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?. Annals of the New York Academy of Sciences, 2012, 1274, 48-59.	1.8	34
34	Overexpression of Rapsyn in Rat Muscle Increases Acetylcholine Receptor Levels in Chronic Experimental Autoimmune Myasthenia Gravis. American Journal of Pathology, 2007, 170, 644-657.	1.9	33
35	The ceramide transporter and the Goodpasture antigen binding protein: one protein â€" one function?. Journal of Neurochemistry, 2010, 113, 1369-1386.	2.1	33
36	Low Current-driven Micro-electroporation Allows Efficient In Vivo Delivery of Nonviral DNA into the Adult Mouse Brain. Molecular Therapy, 2010, 18, 1183-1191.	3.7	31

#	Article	IF	Citations
37	Goodpasture Antigen-binding Protein/Ceramide Transporter Binds to Human Serum Amyloid P-Component and Is Present in Brain Amyloid Plaques. Journal of Biological Chemistry, 2012, 287, 14897-14911.	1.6	31
38	Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model. Radiotherapy and Oncology, 2015, 116, 438-442.	0.3	30
39	Autoimmunity in psychotic disorders. Where we stand, challenges and opportunities. Autoimmunity Reviews, 2019, 18, 102348.	2.5	30
40	Immunoregulation in Experimental Autoimmune Myasthenia Gravis-about T Cells, Antibodies, and Endplates. Annals of the New York Academy of Sciences, 2003, 998, 308-317.	1.8	29
41	Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis. Experimental Neurology, 2015, 270, 29-40.	2.0	27
42	Guidelines for pre-clinical assessment of the acetylcholine receptor-specific passive transfer myasthenia gravis modelâ€"Recommendations for methods and experimental designs. Experimental Neurology, 2015, 270, 3-10.	2.0	25
43	Autoantibodies in Neuropsychiatric Disorders. Antibodies, 2016, 5, 9.	1.2	22
44	TrkB in the hippocampus and nucleus accumbens differentially modulates depression-like behavior in mice. Behavioural Brain Research, 2016, 296, 15-25.	1.2	22
45	Synergistic Effects of NOTCH/Î³-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells. Frontiers in Oncology, 2018, 8, 460.	1.3	22
46	Improvement ofIn VivoTransfer of Plasmid DNA in Muscle: Comparison of Electroporation versus Ultrasound. Drug Delivery, 2007, 14, 273-277.	2.5	21
47	Complement Activation by Ceramide Transporter Proteins. Journal of Immunology, 2014, 192, 1154-1161.	0.4	21
48	<i>Treatment of Myasthenia Gravis by Preventing Acetylcholine Receptor Modulation</i>. Annals of the New York Academy of Sciences, 2008, 1132, 174-179.	1.8	19
49	Characterization of the thymus in Lrp4 myasthenia gravis: Four cases. Autoimmunity Reviews, 2019, 18, 50-55.	2.5	18
50	Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. Journal of Neuroimmunology, 2008, 201-202, 111-120.	1.1	17
51	Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient. Scientific Reports, 2017, 7, 14426.	1.6	17
52	Neuropathy-Induced Spinal GAP-43 Expression Is Not a Main Player in the Onset of Mechanical Pain Hypersensitivity. Journal of Neurotrauma, 2011, 28, 2463-2473.	1.7	16
53	CERTL reduces C16 ceramide, amyloid-Î² levels, and inflammation in a model of Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 45.	3.0	16
54	Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding. Neurobiology of Disease, 2009, 35, 14-23.	2.1	15

#	Article	IF	Citations
55	Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders. Frontiers in Genetics, 2013, 4, 181.	1.1	14
56	Neuronal Surface Autoantibodies in Neuropsychiatric Disorders: Are There Implications for Depression?. Frontiers in Immunology, 2017, 8, 752.	2.2	14
57	Proteomic analysis of rat tibialis anterior muscles at different stages of experimental autoimmune myasthenia gravis. Journal of Neuroimmunology, 2013, 261, 141-145.	1.1	12
58	Silencing of Dok-7 in Adult Rat Muscle Increases Susceptibility to Passive Transfer Myasthenia Gravis. American Journal of Pathology, 2016, 186, 2559-2568.	1.9	12
59	The effect of Mindfulness-Based Stress Reduction on wound healing: a preliminary study. Journal of Behavioral Medicine, 2018, 41, 385-397.	1.1	12
60	Generation of polyclonal antibodies directed against G protein-coupled receptors using electroporation-aided DNA immunization. Journal of Pharmacological and Toxicological Methods, 2008, 58, 27-31.	0.3	11
61	Synthesis, Radiosynthesis, and Preliminary in vitro and in vivo Evaluation of the Fluorinated Ceramide Trafficking Inhibitor (HPA-12) for Brain Applications. Journal of Alzheimer's Disease, 2017, 60, 783-794.	1.2	11
62	MuSK myasthenia gravis and Lambertâ€“Eaton myasthenic syndrome in the same patient. Clinical Neurology and Neurosurgery, 2012, 114, 795-797.	0.6	10
63	Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys. Scientific Reports, 2017, 7, 992.	1.6	10
64	Novel neuronal surface autoantibodies in plasma of patients with depression and anxiety. Translational Psychiatry, 2020, 10, 404.	2.4	10
65	The expression of the Goodpasture antigen-binding protein (ceramide transporter) in adult rat brain. Journal of Chemical Neuroanatomy, 2009, 38, 97-105.	1.0	9
66	Alpha7 acetylcholine receptor autoantibodies are rare in sera of patients diagnosed with schizophrenia or bipolar disorder. PLoS ONE, 2018, 13, e0208412.	1.1	9
67	Ceramide analog [18F]F-HPA-12 detects sphingolipid disbalance in the brain of Alzheimerâ€™s disease transgenic mice by functioning as a metabolic probe. Scientific Reports, 2020, 10, 19354.	1.6	9
68	Absence of Autoantibodies Against Neuronal Surface Antigens in Sera of Patients With Psychotic Disorders. JAMA Psychiatry, 2020, 77, 322.	6.0	8
69	Altered sphingolipid function in Alzheimer's disease; a gene regulatory network approach. Neurobiology of Aging, 2021, 102, 178-187.	1.5	8
70	In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity. Scientific Reports, 2016, 6, 22198.	1.6	8
71	Reduced thymic expression of ErbB receptors without auto-antibodies against synaptic ErbB in myasthenia gravis. Journal of Neuroimmunology, 2011, 232, 158-165.	1.1	7
72	Effects of Sex, Age, and Apolipoprotein E Genotype on Brain Ceramides and Sphingosine-1-Phosphate in Alzheimerâ€™s Disease and Control Mice. Frontiers in Aging Neuroscience, 2021, 13, 765252.	1.7	7

#	Article	IF	Citations
73	Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders. Autoimmunity Reviews, 2022, 21, 103104.	2.5	7
74	Autoantigen induced clonal expansion in immortalized B cells from the peripheral blood of multiple sclerosis patients. Journal of Neuroimmunology, 2013, 261, 98-107.	1.1	6
75	The search for an autoimmune origin of psychotic disorders: Prevalence of autoantibodies against hippocampus antigens, glutamic acid decarboxylase and nuclear antigens. Schizophrenia Research, 2021, 228, 462-471.	1.1	6
76	Ex Vivo and in Vivo Administration of Fluorescent CNA35 Specifically Marks Cardiac Fibrosis. Molecular Imaging, 2014, 13, 7290.2014.00036.	0.7	5
77	Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells. Journal of Visualized Experiments, 2015, , e52830.	0.2	5
78	Low prevalence of Merkel cell polyomavirus in human epithelial thymic tumors. Thoracic Cancer, 2019, 10, 445-451.	0.8	5
79	FTY720 decreases ceramides levels in the brain and prevents memory impairments in a mouse model of familial Alzheimerâ€™s disease expressing APOE4. Biomedicine and Pharmacotherapy, 2022, 152, 113240.	2.5	5
80	Passive transfer models of myasthenia gravis with muscleâ€specific kinase antibodies. Annals of the New York Academy of Sciences, 2018, 1413, 111-118.	1.8	4
81	Detection of Peptide-Based Nanoparticles in Blood Plasma by ELISA. PLoS ONE, 2015, 10, e0126136.	1.1	4
82	Autoimmune Encephalitis With mGluR1 Antibodies Presenting With Epilepsy, but Without Cerebellar Signs. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, e1171.	3.1	4
83	Glycine receptor antibodies in PERM: a new channelopathy. Brain, 2014, 137, 2115-2116.	3.7	3
84	Delivery of DNA into the Central Nervous System via Electroporation. Methods in Molecular Biology, 2014, 1121, 157-163.	0.4	3
85	Myasthenia gravis: subgroup classifications. Lancet Neurology, The, 2016, 15, 356-357.	4.9	2
86	Unchanged expression of the ceramide transfer protein in the acute 6-OHDA neurodegenerative model. Neuroscience Letters, 2012, 506, 39-43.	1.0	1
87	Addendum: Hoffmann, C.; et al. Autoantibodies in Neuropsychiatric Disorders. Antibodies 2016, 5, 9. Antibodies, 2018, 7, 33.	1.2	1
88	Immunofluorescence Labeling of Lipid-Binding Proteins CERTs to Monitor Lipid Raft Dynamics. Methods in Molecular Biology, 2021, 2187, 327-335.	0.4	1
89	Animal Models of Myasthenia Gravis for Preclinical Evaluation. , 2018, , 61-70.		0
90	Unidentified Neuronal Surface IgG Autoantibodies in a Case of Hashimoto's Encephalopathy. Frontiers in Immunology, 2020, 11, 1358.	2.2	0